Loading, Please Wait...
BALTIMORE, April 26, 2019 (GLOBE NEWSWIRE) -- Asklepion Pharmaceuticals, LLC (“Asklepion” or “the Company”), a biotechnology company focused on the development of novel therapeutics for rare pediatric diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent 10,265,286, titled: “Sequelae of Cardiopulmonary Bypass-Induced Pulmonary Injury.” The patent covers a method for using IV-Citrulline to maintain the coupling of endothelial nitric oxide synthase (eNOS) to reduce the incidence or severity of cardiopulmonary bypass-induced pulmonary injury due to free radical formation in a patient during cardiopulmonary bypass. Assigned to Vanderbilt University, this newly issued patent is part of a family of patents and patent applications to which Asklepion holds the exclusive worldwide rights. The allowed claims are expected to expire at the end of June 2036.
Citrulline is a urea cycle intermediate, an important precursor of nitric oxide and maintains coupling of endothelial nitric oxide synthase. Studies have shown that that cardiopulmonary bypass used for correction of congenital heart defects causes a significant decrease in urea cycle function with a large decrease in availability of urea cycle-derived precursors of nitric oxide synthesis.
Asklepion Pharmaceuticals is a Baltimore-based, biotechnology company, focused on the discovery, development, and commercialization of endogenous pharmaceutical products to help patients who have little to no therapeutic options due to the rarity of their conditions. The Company is currently conducting a Phase 3 trial to determine whether IV-citrulline is effective and safe in the prevention of clinical sequelae of acute lung injury in pediatric subjects undergoing surgery for congenital heart defects. More information about the trial can be found on www.clinicaltrials.gov/ct2/show/NCT00335244.
For more information on the company, please visit www.asklepionpharm.com.